top 10

An experimental lupus drug from AstraZeneca ( NYSE : AZN ) significantly improved the symptoms of the chronic , autoimmune disease lupus in a mid-stage clinical trial . Sifalimumab targets interferon , a protein involved in inflammation , and the drug was reported to improve symptoms at all doses . Sifalimumab is one of two drugs for lupus being developed by AstraZeneca ’ s biotech unit MedImmune .

www . astrazeneca . com

28 January 2015